Richard Law
Stock Analyst at Goldman Sachs
(2.25)
# 2,561
Out of 4,883 analysts
64
Total ratings
37.93%
Success rate
1.78%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Richard Law
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OLMA Olema Pharmaceuticals | Maintains: Buy | $20 → $18 | $4.53 | +297.35% | 5 | May 14, 2025 | |
| SLN Silence Therapeutics | Maintains: Sell | $4 → $3 | $5.69 | -47.28% | 3 | May 9, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Neutral | $15 → $13 | $2.88 | +351.39% | 3 | May 9, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Neutral | $36 → $31 | $22.11 | +40.21% | 3 | May 9, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Buy | $31 → $27 | $15.23 | +77.28% | 3 | May 7, 2025 | |
| VKTX Viking Therapeutics | Initiates: Neutral | $30 | $27.72 | +8.23% | 1 | Apr 8, 2025 | |
| MLTX MoonLake Immunotherapeutics | Maintains: Buy | $82 → $73 | $47.86 | +52.53% | 3 | Feb 27, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $28 → $24 | $14.29 | +67.95% | 6 | Feb 13, 2025 | |
| MRUS Merus | Initiates: Buy | $73 | $53.33 | +36.88% | 1 | Nov 21, 2024 | |
| GLUE Monte Rosa Therapeutics | Reiterates: Neutral | $11 | $4.73 | +132.80% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $31 | $11.21 | +176.54% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $47 | $19.88 | +136.42% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $63 | $51.67 | +21.93% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $37 | $44.53 | -16.91% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $76 | $10.73 | +608.29% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $14 | $2.56 | +446.88% | 3 | May 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $61 | $7.90 | +672.15% | 4 | May 8, 2023 |
Olema Pharmaceuticals
May 14, 2025
Maintains: Buy
Price Target: $20 → $18
Current: $4.53
Upside: +297.35%
Silence Therapeutics
May 9, 2025
Maintains: Sell
Price Target: $4 → $3
Current: $5.69
Upside: -47.28%
Rocket Pharmaceuticals
May 9, 2025
Maintains: Neutral
Price Target: $15 → $13
Current: $2.88
Upside: +351.39%
Celldex Therapeutics
May 9, 2025
Maintains: Neutral
Price Target: $36 → $31
Current: $22.11
Upside: +40.21%
Viridian Therapeutics
May 7, 2025
Maintains: Buy
Price Target: $31 → $27
Current: $15.23
Upside: +77.28%
Viking Therapeutics
Apr 8, 2025
Initiates: Neutral
Price Target: $30
Current: $27.72
Upside: +8.23%
MoonLake Immunotherapeutics
Feb 27, 2025
Maintains: Buy
Price Target: $82 → $73
Current: $47.86
Upside: +52.53%
Mineralys Therapeutics
Feb 13, 2025
Maintains: Buy
Price Target: $28 → $24
Current: $14.29
Upside: +67.95%
Merus
Nov 21, 2024
Initiates: Buy
Price Target: $73
Current: $53.33
Upside: +36.88%
Monte Rosa Therapeutics
Aug 11, 2023
Reiterates: Neutral
Price Target: $11
Current: $4.73
Upside: +132.80%
Aug 11, 2023
Reiterates: Neutral
Price Target: $31
Current: $11.21
Upside: +176.54%
Aug 9, 2023
Maintains: Neutral
Price Target: $46 → $47
Current: $19.88
Upside: +136.42%
Aug 8, 2023
Maintains: Neutral
Price Target: $62 → $63
Current: $51.67
Upside: +21.93%
Aug 4, 2023
Maintains: Neutral
Price Target: $36 → $37
Current: $44.53
Upside: -16.91%
Jun 13, 2023
Reiterates: Outperform
Price Target: $76
Current: $10.73
Upside: +608.29%
May 8, 2023
Maintains: Neutral
Price Target: $15 → $14
Current: $2.56
Upside: +446.88%
May 8, 2023
Reiterates: Outperform
Price Target: $61
Current: $7.90
Upside: +672.15%